Lung Adenocarcinoma Genomic Features Differ in East Asians, Europeans
By LabMedica International staff writers Posted on 18 Feb 2020 |
Image: Histopathology of Lung adenocarcinoma (Photo courtesy of Nikon).
Lung adenocarcinoma is a subtype of non-small cell lung cancer (NSCLC). Lung adenocarcinoma is categorized as such by how the cancer cells look under a microscope. Lung adenocarcinoma starts in glandular cells, which secrete substances such as mucus, and tends to develop in smaller airways, such as alveoli.
Lung cancer is the world’s leading cause of cancer death and shows strong ancestry disparities. Lung adenocarcinoma is a common cancer and leads to more than one million deaths each year. A new analysis has found that lung tumors isolated from patients of East Asian ancestry have a less complex genomic architecture than tumors from European patients.
Scientists from the Genome Institute of Singapore (A*STAR, Singapore) and their associates characterized the genomic landscape of lung cancer among East Asians, generating a genomic and transcriptomic dataset encompassing more than 300 lung cancer patients of Chinese ancestry. They sequenced the exomes and transcriptomes of 213 Chinese lung adenocarcinoma patients from Singapore and combined that dataset with previously published whole-exome sequencing data on 92 Chinese patients from another cohort. By comparing the genomic and transcriptomic data from these 305 individuals to that of 249 lung adenocarcinoma patients of European ancestry from The Cancer Genome Atlas, they uncovered differences in tumor mutational burden and driver genes between the groups.
The team reported that overall, East Asian patients' tumors had fewer genomic alterations, with a median tumor mutational burden of 2.04 per Mb, as compared to a median 5.08 per Mb among European patients. While this burden was influenced by patients' smoking status, even among smokers, East Asian patients had a lower median tumor mutational burden than European patients. At the same time, the number and nature of driver mutations differed between tumors from East Asian and European patients. In East Asian patients, alterations affecting the EGFR, TP53, and KRAS genes were the most common driver mutations and nonsmokers had an average 2.08 driver mutations, as compared to an average 2.65 driver mutations among European nonsmokers. Additionally, East Asian patients had fewer copy number variations.
By analyzing the transcriptomic profiles of the tumor samples, the scientists teased out three different lung cancer sub-clusters. Two of these were similar to the terminal respiratory unit (TRU) and proximal inflammatory sub-clusters previously found in European patients, but the third was specific to East Asians. That sub-cluster, dubbed TRU-I, was marked by the upregulation of inflammation-associated genes and increased immune infiltration. This phenotype could help identify patients who might be more likely to benefit from immunotherapy or immune checkpoint blockade treatment.
While they found that patients' clinical features could predict their outcomes, they noted that genomic features could also predict patient survival. These predictions were more accurate for East Asian than European patients, which they attributed to their more stable tumor genomes. The authors concluded that their study elucidated a comprehensive genomic landscape of East Asian ancestry lung adenocarcinomas and highlighted important ancestry differences between the two cohorts. The study was published on February 3, 2020 in the Nature Genetics.
Related Links:
Genome Institute of Singapore
Lung cancer is the world’s leading cause of cancer death and shows strong ancestry disparities. Lung adenocarcinoma is a common cancer and leads to more than one million deaths each year. A new analysis has found that lung tumors isolated from patients of East Asian ancestry have a less complex genomic architecture than tumors from European patients.
Scientists from the Genome Institute of Singapore (A*STAR, Singapore) and their associates characterized the genomic landscape of lung cancer among East Asians, generating a genomic and transcriptomic dataset encompassing more than 300 lung cancer patients of Chinese ancestry. They sequenced the exomes and transcriptomes of 213 Chinese lung adenocarcinoma patients from Singapore and combined that dataset with previously published whole-exome sequencing data on 92 Chinese patients from another cohort. By comparing the genomic and transcriptomic data from these 305 individuals to that of 249 lung adenocarcinoma patients of European ancestry from The Cancer Genome Atlas, they uncovered differences in tumor mutational burden and driver genes between the groups.
The team reported that overall, East Asian patients' tumors had fewer genomic alterations, with a median tumor mutational burden of 2.04 per Mb, as compared to a median 5.08 per Mb among European patients. While this burden was influenced by patients' smoking status, even among smokers, East Asian patients had a lower median tumor mutational burden than European patients. At the same time, the number and nature of driver mutations differed between tumors from East Asian and European patients. In East Asian patients, alterations affecting the EGFR, TP53, and KRAS genes were the most common driver mutations and nonsmokers had an average 2.08 driver mutations, as compared to an average 2.65 driver mutations among European nonsmokers. Additionally, East Asian patients had fewer copy number variations.
By analyzing the transcriptomic profiles of the tumor samples, the scientists teased out three different lung cancer sub-clusters. Two of these were similar to the terminal respiratory unit (TRU) and proximal inflammatory sub-clusters previously found in European patients, but the third was specific to East Asians. That sub-cluster, dubbed TRU-I, was marked by the upregulation of inflammation-associated genes and increased immune infiltration. This phenotype could help identify patients who might be more likely to benefit from immunotherapy or immune checkpoint blockade treatment.
While they found that patients' clinical features could predict their outcomes, they noted that genomic features could also predict patient survival. These predictions were more accurate for East Asian than European patients, which they attributed to their more stable tumor genomes. The authors concluded that their study elucidated a comprehensive genomic landscape of East Asian ancestry lung adenocarcinomas and highlighted important ancestry differences between the two cohorts. The study was published on February 3, 2020 in the Nature Genetics.
Related Links:
Genome Institute of Singapore
Latest Pathology News
- New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers
- Faster Measurement of Vibrational Fingerprint of Molecules to Advance Biomedical Diagnostics
- Clinical Antibody Test to Quickly Detect Even Low Levels of Common Parasitic Infection
- Pioneering Microscopy Technique Improves Diagnosis of Glioblastoma Brain Tumors
- AI-Based Breast Cancer Test Uses Routine Digital Histopathology Images for Risk Stratification
- AI Model Identifies Sex-Specific Risks Associated with Brain Tumors
- Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow
- AI Technology Accurately Predicts Breast Cancer Risk Via ‘Zombie Cells’
- Liquid Biopsy Solution Enables Non-Invasive Sample Collection and Direct Cell-Free DNA Stabilization from Urine
- Innovative AI Tool Uses Digitized Whole-Slide Images for Intermediate-Risk Prostate Cancer Management
- AI-Based Tissue Staining Detects Amyloid Deposits Without Chemical Stains or Polarization Microscopy
- Super-Resolution Imaging Detects Parkinson's 20 Years Before First Motor Symptoms Appear
- New Technology for Sampling Body Liquids in Confined Spaces to Enable Early Cancer Detection
- New Technology Holistically Images Deep Living Tissue for The First Time
- New Molecular Sensor Enables Fluorescence Imaging for Assessing Sarcoma Severity
- New Biology Lab Tools Speed Up Tumor Dissection